January Capital Club

January 21st, 2022 at 10:00 AM Central Time (US and Canada)

About Excelsior Capital Club

Because we can only bring a certain amount of deals to our investor network, we’ve partnered with outside firms to bring you access to the best alternative investing opportunities. 

Upcoming Pitch Breakdown

  • 0:00-10:00: Solas Bioventures
  • 10:00-15:00: Solas Bioventures Q&A
  • 15:00-25:00: LotusGroup Longevity Fund
  • 25:00-30:00: LotusGroup Longevity Fund Q&A
  • 30:00-40:00: irrvrntVC
  • 40:00-45:00: irrvrntVC Q&A

      Register for the next pitch today!

      Upcoming Pitch Details

      January 21st, 2022 at 10:00 AM Central Time (US and Canada)
        In our next Excelsior Capital Club pitch, you’ll have the opportunity to hear from our presenters: Raphael Martorello, Scott Rader and Andrew Gluck.
      aaron-abrahms-2

      LotusGroup Longevity Fund

      Deal Sector: Life Settlements

      Total Raise: $69M

      LotusGroup Capital (“LGC”) was founded in 2018 out of the private alts group of sister firm LotusGroup Advisors (collectively “LotusGroup”). LotusGroup has a 17-year regulatory track record and both firms are registered as RIAs with the SEC. Led by CIO Mr. Raphael Martorello, LGC’s Asset Management Team is comprised of professionals in life settlement sourcing,
      valuation, closing, servicing, portfolio management, and actuarial modeling. Combined, the team has over 50 years of life settlements experience and has transacted and managed several billion dollars of life settlements.

      The LotusGroup Longevity Fund is a differentiated life settlements strategy. The fund focuses on producing uncorrelated yield and total returns to traditional investments.

      Presented By: Raphael Martorello | Connect on Linkedin

      aaron-abrahms-2

      Solas Bioventures

      Deal Sector: Venture Capital and Private Equity

      Total Raise: $1M

      Solas BioVentures focuses on early stage biopharmaceuticals, medical devices, diagnostics, digital health technologies and related opportunities in medicine. The Investment Team combines decades of medical, biotechnology, operational, managerial, and financial experiences as well as having been profitably engaged in investing in these same types of companies independently. The Team involves the Solas Limited Partners from the medical field when reviewing opportunities in their area of clinical expertise.

      Presented By: Scott Rader | Connect on Linkedin

      excelsior-capital-logo-icon-white

      irrvrntVC

      Deal Sector: Early-stage VC Fund

      Total Raise: $250-500K

      irrvrntVC invests $250K-$500K at the earliest stages in DTC, AdTech, & NextGen Commerce companies. irrvrnt is a Solo Capitalist fund led by Andrew Gluck. Andrew spent the last three years angel investing in some of the most successful early-stage companies including Lunchbox, Caraway, Branch, Coop Commerce, and more. Prior to that he co-founded and ran Agency Within, the largest independent digital marketing agency with a focus on direct-response, data-driven marketing, where he managed $1B+ in spend for clients like Nike, Billie and Zola.

      Presented By: Andrew Gluck | Connect on Linkedin

      Excelsior Capital and Brian C. Adams are not an investment advisory service and is not a registered investment advisor or broker/dealer and has performed no due diligence and does not endorse any investment services, strategies, managers or investments listed on the Excelsior Capital Club.You should perform your own extensive due diligence.

      Excelsior Capital

      104 Woodmont Blvd, Suite 203
      Nashville, TN 37205

      investors@excelsiorgp.com

      w

      Livechat

      Disclaimer: Under no circumstances should any information presented on this website be construed as an offer to sell, or solicitation of an offer to purchase any securities or other investments. This website does not contain the information that an investor should consider or evaluate to make a potential investment. Other materials related to investments in entities managed by Excelsior Capital are not available to the general public.